These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 29096154)

  • 1. Meta-analysis of safety and efficacy for direct oral anticoagulation treatment of non-valvular atrial fibrillation in relation to renal function.
    Zou R; Tao J; Shi W; Yang M; Li H; Lin X; Yang S; Hua P
    Thromb Res; 2017 Dec; 160():41-50. PubMed ID: 29096154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
    Hijazi Z; Hohnloser SH; Oldgren J; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Reilly PA; Siegbahn A; Yusuf S; Wallentin L
    Circulation; 2014 Mar; 129(9):961-70. PubMed ID: 24323795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac and renal outcomes of direct oral anticoagulants in patients with atrial fibrillation.
    Wang YT; Chen JH; Liao SF; Chen YJ; Lip GYH; Yeh JS
    Eur J Clin Invest; 2024 Jan; 54(1):e14086. PubMed ID: 37635402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis.
    Deitelzweig S; Farmer C; Luo X; Li X; Vo L; Mardekian J; Fahrbach K; Ashaye A
    Curr Med Res Opin; 2018 Mar; 34(3):487-498. PubMed ID: 29188721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variation of renal function over time is associated with major bleeding in patients treated with direct oral anticoagulants for atrial fibrillation.
    Becattini C; Giustozzi M; Ranalli MG; Bogliari G; Cianella F; Verso M; Agnelli G; Vedovati MC
    J Thromb Haemost; 2018 May; 16(5):833-841. PubMed ID: 29460334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation.
    Oertel LB; Fogerty AE
    J Am Assoc Nurse Pract; 2017 Sep; 29(9):551-561. PubMed ID: 28805310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased risk of renal impairment in atrial fibrillation patients receiving non-vitamin K antagonist oral anticoagulants: A pooled analysis of randomized controlled trials and real-world studies.
    Zhang C; Gu ZC; Ding Z; Shen L; Pan MM; Zheng YL; Lin HW; Pu J
    Thromb Res; 2019 Feb; 174():16-23. PubMed ID: 30551039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-Analysis of Renal Function on the Safety and Efficacy of Novel Oral Anticoagulants for Atrial Fibrillation.
    Del-Carpio Munoz F; Gharacholou SM; Munger TM; Friedman PA; Asirvatham SJ; Packer DL; Noseworthy PA
    Am J Cardiol; 2016 Jan; 117(1):69-75. PubMed ID: 26698882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
    Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Direct Oral Anticoagulants Compared to Warfarin in Prevention of Thromboembolic Events Among Elderly Patients with Atrial Fibrillation.
    Kailas SD; Thambuluru SR
    Cureus; 2016 Oct; 8(10):e836. PubMed ID: 27900231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
    Fox KA; Piccini JP; Wojdyla D; Becker RC; Halperin JL; Nessel CC; Paolini JF; Hankey GJ; Mahaffey KW; Patel MR; Singer DE; Califf RM
    Eur Heart J; 2011 Oct; 32(19):2387-94. PubMed ID: 21873708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 14. Direct oral anticoagulants use in elderly patients with non valvular atrial fibrillation: state of evidence.
    Benedetti G; Neccia M; Agati L
    Minerva Cardioangiol; 2018 Jun; 66(3):301-313. PubMed ID: 29125269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.
    Spencer RJ; Amerena JV
    Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of the direct-acting anticoagulants in patients with atrial fibrillation: a meta-analysis.
    Rong F; Jia B; Huang P; Lynn HS; Zhang W
    Thromb Res; 2015 Jun; 135(6):1117-23. PubMed ID: 25891842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian meta-analysis approach.
    Verdecchia P; Angeli F; Bartolini C; De Filippo V; Aita A; Di Giacomo L; Poltronieri C; Lip GY; Reboldi G
    Expert Opin Drug Saf; 2015 Jan; 14(1):7-20. PubMed ID: 25311731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation.
    Khan F; Huang H; Datta YH
    J Thromb Thrombolysis; 2016 Nov; 42(4):573-8. PubMed ID: 27520093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.